Fingolimod (FTY720), an immunomodulator that acts on sphingosine-1-phosphate receptors, is the first oral disease-modifying agent to be approved by the US FDA for the treatment of relapsing forms ...
Sphingosine is a membrane component in all cells and constitutes 25% of the lipid in the myelin sheath. Sphingosine is phosphorylated by ubiquitously expressed sphingosine kinases. S1P regulates ...
Novartis' small molecule FTY720 (fingolimod), now in phase 3, is a potential threat to Biogen Idec's lucrative multiple sclerosis (MS) franchise. But in June Novartis reported that two phase 3 ...
Still in the game, but just barely, is Basel–based Novartis' S1P1 modulator FTY720 (fingolimod), which has run into serious safety issues in pivotal testing. Table 1 Selected MS therapies in ...